Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Halozyme Therapeutics and Roche have dosed the first patient with subcutaneous (SC) MabThera (rituximab), an anticancer biologic, in a Phase III trial using Enhanze technology (rHuPH20, recombinant human hyaluronidase).
Subscribe to our email newsletter
SC MabThera has been developed through collaboration between Halozyme and Roche, in which Halozyme has agreed to apply its proprietary Enhanze technology to Roche’s biological therapeutic compounds.
MabThera is currently approved to treat non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukaemia (CLL) using treatments that are administered intravenously.
The new technology allows patients with NHL to receive MabThera in less than 10 minutes through an SC injection at their physician office.
The administration of SC MabThera enables patients with NHL to receive much shorter drug administration.
In addition, SC MabThera administration outside IV infusion centre or hospital setting could reduce costs and help maximise the efficient use of hospital resources.